Abstract | BACKGROUND: MATERIALS AND METHODS: We analyzed the cell viability after combinational treatment of TGFβ receptor I (TβRI) inhibitors, SB431542 and SB525334 with gemcitabine in pancreatic cancer cells. In addition, apoptotic cell death and cell migration were measured. RESULTS: Combination with TβRI inhibitors significantly augmented the cytotoxicity of gemcitabine in both parental and gemcitabine resistant pancreatic cancer cells. SB525334 significantly increased apoptotic cell death in gemcitabine-resistant cells. Treatment of SB525334 also affected the AKT signalling pathway, which plays a crucial role in gemcitabine resistance. Migration assay also revealed that blocking TβRI reduces cell migration. CONCLUSION:
|
Authors | Yeon Jeong Kim, Jae Seok Hwang, Young Bin Hong, Insoo Bae, Yeon-Sun Seong |
Journal | Anticancer research
(Anticancer Res)
Vol. 32
Issue 3
Pg. 799-806
(Mar 2012)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 22399597
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline
- Antimetabolites, Antineoplastic
- Imidazoles
- Quinoxalines
- Receptors, Transforming Growth Factor beta
- Deoxycytidine
- Protein Serine-Threonine Kinases
- Receptor, Transforming Growth Factor-beta Type I
- Gemcitabine
|
Topics |
- Antimetabolites, Antineoplastic
- Cell Line, Tumor
- Deoxycytidine
(analogs & derivatives, pharmacology)
- Humans
- Imidazoles
(pharmacology)
- Pancreatic Neoplasms
(pathology)
- Protein Serine-Threonine Kinases
(antagonists & inhibitors)
- Quinoxalines
(pharmacology)
- Receptor, Transforming Growth Factor-beta Type I
- Receptors, Transforming Growth Factor beta
(antagonists & inhibitors)
- Gemcitabine
|